A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1) SUCCESSOR-1

What's the purpose of this trial?

The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Participant has documented diagnosis of MM and measurable disease, defined as any of the following:

    • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
    • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
    • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
  • Participants received 1 to 3 prior lines of antimyeloma therapy.
  • Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

Exclusion Criteria:

  • Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor.
  • For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
  • Participant has had prior treatment with CC-92480 or pomalidomide.

Other protocol-defined criteria apply.

Additional Trial Information

Phase 3

Enrollment: 760 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Sharp Memorial Hospital (Amtower Cancer Institute)

San Diego, CA

Not Yet Accepting

James R Berenson, MD, Inc.

West Hollywood, CA

Not Yet Accepting


University Cancer and Blood Center

Athens, GA

Open and Accepting


University of Illinois at Chicago

Chicago, IL

Not Yet Accepting


Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Not Yet Accepting


University of Kansas Cancer Center

Kansas City, KS

Not Yet Accepting


Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Not Yet Accepting


Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting


University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Not Yet Accepting


Hattiesburg Clinic

Hattiesburg, MS

Open and Accepting

New York

Jonah Cancer Care Center & ECMC

Buffalo, NY

Not Yet Accepting

Northwell Health Monter Cancer Center

Lake Success, NY

Not Yet Accepting

Rochester General Hospital

Rochester, NY

Not Yet Accepting

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Not Yet Accepting


Cleveland Clinic Taussig Cancer Institute

Cleveland, OH

Not Yet Accepting


West Penn Hospital (Allegheny Health Network)

Pittsburgh, PA

Not Yet Accepting

WellSpan Health-York Cancer Center

York, PA

Not Yet Accepting


West Cancer Center (East Campus - Germantown) East Campus

Germantown, TN

Open and Accepting


UT Health San Antonio MD Anderson Cancer Center Mays Cancer Center

San Antonio, TX

Not Yet Accepting


Utah Cancer Specialists Cancer Center

Salt Lake City, UT

Open and Accepting


VA Puget Sound Health Care System

Seattle, WA

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors